Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 trial with ART-101

Next Previous
Trial Profile

A Phase 1 trial with ART-101

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ART-101-Archeus-Technologies (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use; First in man

Most Recent Events

  • 02 Dec 2025 According to Archeus Technologies media release, company announced that it has dosed the first patient in its Phase 1 clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC).
  • 02 Dec 2025 According to Archeus Technologies media release, Status changed from planning to recruiting.
  • 20 Jun 2025 According to Archeus Technologies media release, the USFDA has cleared the IND application for ART 101 enabling the company to initiate a Phase 1 clinical trial in men with metastatic castration-resistant prostate cancer (mCRPC), which is expected to start later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top